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Differences in the Mechanism of Collagen Lattice
Contraction by Myofibroblasts and Smooth
Muscle Cells
J. C. Dallon ∗ , and H. Paul Ehrlich †
∗

Department of Mathematics, Brigham Young University, Provo, UT 84602-6539, and † Division of Plastic Surgery, Department of Surgery, Milton S. Hershey Medical Center,
Hershey, PA

Both rat derived vascular smooth muscle cells (SMC) and human
myofibroblasts contain α smooth muscle actin (SMA), but they utilize different mechanisms to contract populated collagen lattices
(PCLs). The difference is in how the cells generate the force that
contracts the lattices. Human dermal fibroblasts transform into myofibroblasts, expressing α-SMA within stress fibers, when cultured
in lattices that remain attached to the surface of a tissue culture
dish. When attached lattices are populated with rat derived vascular SMC, the cells retain their vascular SMC phenotype. Comparing
the contraction of attached PCLs when they are released from the
culture dish on day 4 shows that lattices populated with rat vascular
SMC contract less than those populated with human myofibroblast. PCL contraction was evaluated in the presence of vanadate
and genistein, which modify protein tyrosine phosphorylation, and
ML-7 and Y-27632, which modify myosin ATPase activity. Genistein and ML-7 had no affect upon either myofibroblast or vascular
SMC-PCL contraction, demonstrating that neither protein tyrosine
kinase nor myosin light chain kinase was involved. Vanadate inhibited myofibroblast-PCL contraction, consistent with a role for protein
tyrosine phosphatase activity with myofibroblast-generated forces.
Y-27632 inhibited both SMC and myofibroblast PCL contraction,
consistent with a central role of myosin light chain phosphatase.

Introduction
The contraction of open wounds is due to forces generated
within granulation tissue that pull the surrounding skin into
the wound [1]. There are 2 proposed mechanisms for generating the forces for wound contraction. The first is mechanotension through contractile forces from a specialized cell
within granulation tissue, the myofibroblast [2]. The other
mechanism is through fibroblast generated tractional forces,
where the packing of fine collagen fibrils into longer, thicker
collagen fiber bundles, compacts granulation tissue [3]. While
both require Myosin ATPase activity, it is generated differently in each mechanism. Myofibroblasts employ “sustained”
myosin ATPase activity [4] and fibroblasts employ “rapid”
myosin ATPase activity [5].
Myosin ATPase produces the energy for the force that
generates the sliding action of myosin-actin filaments within
the cell’s cytoskeleton. Myosin ATPase is involved in numerous cell activities, including generating the forces for both cell
contraction and cell locomotion. The phosphorylation of the
regulatory peptide at serine 19 of myosin light chain (MLC),
optimizes myosin ATPase activity [6]. MLC devoid of phosphorylated serine 19 has minimal myosin ATPase activity.
There are “sustained” and “rapid” myosin ATPase activities,
which both require phosphorylated MLC at serine 19. Rapid
myosin ATPase activity is dependent upon myosin light chain
kinase (MLCK), which is a calcium-calmodulin dependent kinase that phosphorylates MLC at serine 19. The dephosphorylation of MLC by MLC phosphatase immediately follows
the myosin relocation on the actin filament [6]. A calmodulin inhibitor or a MLCK inhibitor blocks rapid myosin AT-

Pase activity. The mechanism for sustained myosin ATPase
is through the inhibition of MLC phosphatase, resulting in
the retention of phosphate within MLC at serine 19 and the
preservation of myosin ATPase activity. MLC phosphatase
can be inhibited by Rho-Rho kinase phosphorylating a tyrosine residue in one of 4 subunits composing the MLC phosphatase enzyme complex [7]. The myofibroblast utilizes the
inhibition of MLC phosphatase activity for generating sustained myosin ATPase activity. Smooth muscle cells can utilize a pathway, involving CPI-17 for regulating MCL phosphatase activity [8].
Contractile forces by blood vessel wall smooth muscle
cell (SMC) are responsible for maintaining blood vessel tone,
whereas contractile force generated by myofibroblasts, the
icon of fibrotic tissues, is the proposed mechanism responsible for producing open wound contraction. Both smooth
muscle cells and myofibroblasts are associated with collagen,
during the generation of contractile forces. Studying these
cell types in a 3-dimensional matrix better mimics the in
vivo situation as compared to these cells in monolayer. Bell
et al., [9] introduced fibroblast populated collagen lattices
(PCL) and studied their contraction. The Bell system uses
a free floating fibroblast PCL, where cell-collagen interactions
lead to the compaction of a 3 dimensional collagen matrix.
The compaction of free floating collagen lattices is though
rapid myosin ATPase activity [5]. With the free floating fibroblast PCL model, fibroblasts remain elongated and do not
express α smooth muscle actin (SMA) in cytoplasmic stress
fibers [10]. Tomasek and coworkers introduced the attacheddelayed-released (ADR) cell PCL contraction model, where
lattices remain attached to their underlying surface for days
before they are released [11]. By the time of release the fibroblast population has transformed into myofibroblasts, expressing α-SMA within stress fibers. Myofibroblasts create tension
via sustained myosin ATPase activity. When the attached
lattice is released, there is a rapid contraction of the lattice
associated with the contraction of the resident myofibroblasts
[4]. Another difference between these lattice contraction models is the end result of collagen organization. The collagen
fibrils in free floating PCL contraction are compacted into
thicker fibrils as lattice contraction proceeds. In the ADRPCL model minimal collagen reorganization occurs [12]. The
mechanism for lattice contraction in the two models is different, where ADR-PCL contraction is mediated by cell contraction and sustained myosin ATPase activity; with free floating
PCL contraction there is no fibroblast contraction, the collagen fibrils are reorganized and rapid myosin ATPase generates
the tractional forces.
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Integrins are critical for lattice contraction [13, 14, 15].
The α2β1 integrin is a major collagen receptor for type I collagen, as well as for other fibrillar collagens [16]. The data suggests that in human dermal fibroblasts the α2β1 integrin plays
an important role in the contraction of collagen lattices [17],
although the α11β1 integrin may also play a role as indicated
in studies with cells from mice [18]. When the α2β1 integrin
is not present, other integrins may be expressed, which can
cause collagen lattice contraction [19]. The capacity to contract free floating collagen lattices among SMC populations
is related to the expression of α2β1 integrin [15]. Monoclonal
antibody to α2 only partially blocked contraction, whereas
antibodies to β1 completely inhibited contraction [20] indicating another integrin also contributes to SMC contraction
of collagen lattices.
Human myofibroblasts and rat derived smooth muscle
cells generate contractile forces using sustained myosin ATPase activity. However, the generation of sustained myosin
ATPase activity differs with the 2 cell types. The differences
in generating sustained myosin ATPase activity with these cell
types is shown by comparing the actions of 4 agents in the contraction of ADR PCLs. The agents are: ML-7, which blocks
MLCK [21]; Y-27632, a Rho-associated kinase (ROCK) inhibitor, which blocks the phosphorylation of a specific peptide
subunit in the MLC phosphatase complex [22]; genistein, a tyrosine kinases inhibitor, which prevents the phosphorylation of
protein tyrosine residues that play a role in cell signaling [23];
and vanadate, which inhibits protein tyrosine phosphatase,
preventing the turnover of protein tyrosine phosphate groups
[24] It is established that the state of protein tyrosine phosphorylation affects smooth muscle contraction [25, 26], the
formation of actin stress fibers and the size of focal adhesions
[27].

Methods
Materials. Dulbecco’s modification of Eagle’s medium (DMEM)
purchased from Life Technologies (Rockville, MD), fetal
bovine serum (FBS) from HyClon (Logan, UT), Y-27632 from
EMD Bioscience (San Diego, CA), ML-7, vanadate, genistein,
monoclonal anti-α Smooth Muscle Actin (α-SMA) all from
Sigma Chemical Co. (St. Louis, MO), donkey anti mouse
antibody from Jackson Immuno Research Laboratories (West
Grove, PA), and Alexa 488 phalloidin from Invitrogen (Carlsbad, CA).
The two cell lines studied were primary human derived
dermal fibroblasts from neonatal foreskin and rat derived SMC
from the intimal thickening of the thoracic aorta 15 days after ballooning, which were a gift form Dr. Augusto Orlandi
[15]. Both cell types were maintained in DMEM with10% FBS
and 15 µg/ml of gentamicin, which is referred to as complete
DMEM.
Casting Populated Collagen Lattices. Each milliliter of fibroblast and SMC-PCL contained 50,000 cells, 1.25 mg of acid
soluble rat tail tendon collagen in 1 mM HCl and complete
DMEM. In a 100 mm tissue culture dish (Falcon BD Labware,
Franklin Lakes, NJ) 0.2 ml drops of cell-collagen-medium mixture were pipetted onto the surface of the dish and allowed to
polymerize before adding 8 ml of complete DMEM. Between 4
and 5 PCLs in each dish were maintained at 37◦ , with 5% CO2
in a water saturated atmosphere incubator for 3 days without
a change of medium. Agents were added 24 hrs before their
release on day 4. Cell PCLs were photographed 10-15 minutes
and 5 hours after their release at a fixed distance, with a ruler
in place and their areas determined by the imaging software
ImageJ program [28]. To compare fibroblasts to myofibrob2

lasts capacity to contract ADR PCL, attached fibroblast PCLs
were released at 24 hrs, a time point, when myofibroblasts are
not present, and at 4 days, a time point, when most of the cell
population had converted into myofibroblasts. Lattice contraction for treated lattices was compared to the contraction
of control untreated lattice areas, using a two-tail, unequal
variance t-test. Significance was P ≤ 0.05.
Immuno-histology.Cell PCLs were fixed in buffered 4 %
paraformaldehyde in cytoskeletal buffer (137mM NaCl; 5mM
KCI; 4mM NaHCO2 ; 2mM MgCl2 ; 3.5 mM glucose; 2mM
EGTA, 1.5 mM K2 HPO4 and 5 mM PIPES pH 6.1) for 5 minutes then transferred to cytoskeletal buffer alone. Cells were
permeablized by treating lattices with 0.1% Triton X-100 in
cytoskeletal buffer for 1 minute. The lattices were incubated
with monoclonal antibody directed to α-SMA, washed 4 times
before a second incubation with rhodamine tagged donkeyanti mouse IgG, Alexa phalloidin to identify filamentous actin
and DAPI to identify nuclei. The lattices were viewed with
a Zeiss Axiovert 135 Microscope with florescence and a 40 x
objective water lens. Digital photographs were taken with a
Photometrics CoolSnapFX digital camera.

Results
At both day 1 and 4 attached SMC PCLs exclusively contained SMCs. In contrast, at day 1 attached fibroblast PCLs
contained over 95% fibroblasts, which did not express α-SMA
staining stress fibers and less than 5% myofibroblasts, cells
that do expressed α-SMA. At 4 days attached fibroblast PCLs
contained 95% myofibroblast (based on counting 117 cells in
20 different images). The release of initially fibroblast PCL
at 1 day or 4 days with a spatula initiated lattice contraction,
which was rapid, during the first 10 minutes and proceeded at
a slower rate over the next 5 hours. Fibroblast PCL released at
1 day showed minimal lattice contraction compared to 4 days
(Table I). Differences at 4 days with lattice contraction were
noted between vascular SMC PCLs and myofibroblast PCLs.
Myofibroblasts were more effective at lattice contraction compared to vascular SMCs (Table I, figures 1 and 2). At 5
hours, the SMC PCLs had contracted by 35% and myofibroblast PCLs had contracted to about 85%. The rate and degree
of either myofibroblast or SMC PCL contraction was not affected by the inclusion of 500 nM ML-7, a MLCK inhibitor,
24 hours before release (figure 1). However, at 4 days the rate
and degree of myofibroblast PCL contraction was strongly inhibited by 500 nM Y-27632 a ROCK inhibitor (figure 1 b),
while SMC PCL contraction was strongly inhibited at 10-15
minutes and less strongly inhibited at 5 hours (figure 1 a).
At 10 to 15 minute after release, Y-27632 treated SMC PCLs
had contracted to about 5% (controls 15%) and myofibroblast
PCLs had contracted to 25% (controls 55%). At 5 hours, Y27632 treated smooth muscle cell PCLs had contracted 20%
(controls 35%) and the myofibroblast PCLs had contracted
by 30% (controls 85%). To test that this was not a result
of toxicity we grew myofibroblasts and SMCs with 25µM and
at 250 µM Y-27632 for 2 days. The higher concentration was
somewhat toxic for the cells, where some cells rounded up. At
the lower concentration there was no evidence of altered cell
behavior and no rounded up cells were seen.
Vanadate and GenisteinVanadate was added to attached
SMC and myofibroblast PCLs at a concentration of 30 µM
24 hours before their release. When protein tyrosine phosphatases were inhibited by vanadate, myofibroblast PCL contraction was inhibited at both 10 minutes and 5 hours (figure 2b). Vanadate significantly inhibited myofibroblast PCL
J. C. Dallon & H. Paul Ehrlich

Table 1: Attached-Released Collagen Lattice Contraction at 1 and 4 Days

Fibroblasts
SMC

a
b

Day 1 time 0
194±8 mm2
201±14

Day 1 10 min
173±7
208±16

Day 1
a
11%
0% NS

Day 4 time 0
133±4
136±19

Day 4 10 min
65±4
128±6

p = 0.01
p = 0.0001

1.2

1.4

*

1.2

1

*

0.8

Control
Y-27632
ML-7

0.6

Lattice Area (cm2)

1
Lattice area (cm2)

Day 4
b
52%
∗
6%

0.8
Control
Y-27632

0.6

ML-7
0.4

0.4
0.2

0.2

0

0
before release

10-15 minutes

5 hours

before release

a: aorta smooth muscle cells

10 minutes

5 hours

b: myofibroblasts

Fig. 1: Bar graphs showing changes in area of ADR cell PCLs at 3 time points for lattices populated with SMC in a) and myofibroblasts in b). Data is
presented for untreated lattices, lattices treated with 500 nM Y-27632, and lattices treated with 500 nM ML-7. Note that treatment with Y-27632 inhibits
lattice contraction for both cell types. The data in a) is the average of two experiments with quadruplicate lattices and in b) the data is from one experiment
and is the average of three and four lattices. The results from b) were duplicated in 2 other experiments. It needs to be noted that in a number of experiments,
some PCLs freed themselves from the surface of the dish before day 4 and therefore could not be included in the study. The * indicates statistical significance
of p < 0.05 as compared to controls. The error bars indicate standard deviation.

1.4

1.2

1.2

1

1

Control
Genistein
Vanadate

0.6

Lattice area (cm2)

Lattice area (cm2)

0.8
0.8

*

Control
Genistein
Vanadate

0.6

0.4
0.4
*
0.2

0.2

0

0
before release

10-15 minutes

5 hours

a: aorta smooth muscle cells

before release

10 minutes

5 hours

b: myofibroblasts

Fig. 2: Bar graphs showing changes in area of ADR cell PCLs at 3 time points for lattices populated with SMC in a) and myofibroblasts in b). Data is
shown for untreated lattices, lattices treated with 30 µM vanadate, and lattices treated with 10 µM genistein. Note that treatment with vanadate significantly
inhibits lattice contraction in myofibroblast PCL. Data in a) was the average of 2 experiments with 4 lattices per experiment. Data in b) was the average of 4
experiments with 4 lattices per experiment. The * indicates statistical significance as compared to control where p < 0.05. The error bars indicate standard
deviation.

contraction (figure 2b), although the effect was not strong
the results are consistent with previous experiments, where a
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more dramatic effect was seen with higher dosages of vanadate
[29]. The differences between treated and untreated lattices
were more pronounced at the 10 minutes period compared to
3

the 5 hour period. SMC PCL contraction was not altered
by added vanadate (figure 2 a). Genistein at 10 µM inhibits
protein tyrosine kinases, and was ineffective at inhibiting lattice contraction of either myofibroblast PCLs or SMC PCLs
(figure 2). Comparing untreated myofibroblast PCLs to genistein treated lattices, showed no change in the rate or final size
5 hours after release. Inhibiting protein tyrosine kinases did
not affect the contraction of released attached PCLs. Again to
test that the effect was not a result of toxicity, myofibroblasts
and SMCs were cultured with 30 µM and 100 µM vanadate
for 2 days. At 100 µM vanadate the cells died and came off
the dish. At 30µM vanadate the cells did not round up and
remained attached and elongated.
Cell morphology When fibroblasts were cast in a collagen lattice that remained attached to the surface of the tissue culture
dish, at 4 days the cells had transformed into a myofibroblast
phenotype, which was identified by the expression of α-SMA
in stress fibers. A single myofibroblast shown in figure 3a had
prominent cytoplasmic stress fibers running in the long axis
of the cell and α-SMA in a perinuclear location. Ten minutes
after the release of a 4 day myofibroblast PLC, contracted
lattices were processed for fluorescent immuno-histology. A
released myofibroblast PCL contained contracted myofibroblasts (figure 3b). The morphology of myofibroblasts was different from that of fibroblasts or SMC. The myofibroblasts
had a stellate shape with several arms reaching out into the
collagen matrix. Unlike the many attached arms found with
myofibroblasts in 4 day released lattices, in the one day released lattices there were few fibroblast arms protruding out
into the collagen matrix. In figure 3c a fibroblast in an attached collagen lattice at 1 day, showed less prominent actin
rich stress fibers and minimal α-SMA staining. A pair of
contracted fibroblasts, which is typical of released 1 day fibroblast PCLs, are presented in figure 3. Fibroblasts at 1
day had less capacity to contract PCLs as compared to myofibroblasts in 4 day PCLs. The cells in an untreated control
myofibroblast PCL had thick α-SMA cytoplasmic stress fibers
(figure 3a), but adding vanadate to a myofibroblast PCL on
day 3, 24 hours before release, the stress fibers were thinner and less prominent on day 4 (figure 3e). When vanadate treated myofibroblast PCLs were released at 4 days the
cells contracted less than controls and they had fewer arms
associated with the collagen fibrils (figure 3f). The vanadate
treated cells had thinner cytoplasmic microfilaments and were
less effective at lattice contraction. Vascular smooth muscle
cells incorporated in attached collagen lattices aggregated into
multi-cellular complexes. When compared to SMC PCLs, fibroblasts in PCL were more independent (compare figure 3a
and 3g). Vascular smooth muscle cells show some degree
of contraction immediately after the lattice was released (see
figure 3h), but did not generate much additional contraction
beyond 10 minutes.

Discussion
Differences in free floating PCLs containing vascular SMC derived from the intimal thickening of a balloon damaged rat
aorta blood vessel has previously been reported [15]. These
differences are associated with cell morphology, where greater
free floating SMC PCL contraction is seen with more elongated vascular SMC derived from young rat aorta [15]. SMC
derived from intimal thickenings on the rat aorta wall are more
compact cells that produce less free floating lattice contraction [15]. The compaction of free floating human fibroblast
PCL requires the translocation of collagen fibrils and their re4

organization into thicker collagen fiber bundles, which occurs
in the absence of any observed cell contraction [3]. Intestinal derived human SMCs cast in free floating collagen lattices
are equal to human dermis derived fibroblasts at contracting
PCLs [30, 31]. Like fibroblast PCL, free floating intestinal
derived SMC PCL contraction proceeds in the absence of established cell contraction. When residing in a contracting free
floating collagen matrix, both fibroblasts and intestinal SMCs
retain an elongated morphology [30]. The mechanism responsible for SMC contraction of free floating PCLs requires the
reorganization of collagen fibrils, which is unrelated to cell
contraction [32]. Free floating vascular SMC PCL contraction starts within 4 to 6 hours after casting the lattice a time,
when α-SMA expression is minimal [15]. As a consequence,
factors other than the presence of α-SMA in cytoskeletal stress
fibers promote lattice contraction. Other factors include integrins that are critical for lattice contraction [13, 14, 15]. The
α2β1 integrin is a major collagen receptor for type I collagen
as well as for other fibrillar collagens [16]. The data suggests that with human dermal fibroblasts the α2β1 integrin
plays an important role in the contraction of collagen lattices
[17]. The capacity to contract free floating PCLs among SMC
populations is related to the expression of α2β1 integrin [15].
The mechanism for the contraction of free floating fibroblast
PCL changes when lattices are cast with a high density of
fibroblasts. Instead of the reorganization of collagen fibrils
generating lattice contraction, with high density populations
of fibroblasts incorporated in collagen lattices, cell elongation
of the spherical shaped cells initially incorporated into PCL,
is the mechanism for lattice contraction [10]. In the high density fibroblast PCL, lattice contraction is completed by 6 hrs,
a time when cell elongation is completed. If this were the situation here, then lattice contraction would be expected to be
completed in the initial 6 hours after casting not at 4 days.
Free floating human fibroblast and rat smooth muscle cell
PCLs cast at a moderate cell density produce lattice contraction linking the reorganization of collagen fibrils with PCL
compaction. Myofibroblasts, the cell phenotype in 4 day attached fibroblast PCL, show greater cell contraction as well
as lattice contraction compared to attached fibroblast PCL
released at 1 day. As compared to 1 day fibroblast PCLs,
by 4 days fibroblasts have transformed into myofibroblasts
and generate more attachments to their surrounding collagen
matrix. When the 4 day myofibroblast PCLs are released,
the contracting cells have more attachment sites within their
surrounding collagen matrix, which results in more collagen
fibrils displaced by each contracting myofibroblast. At 1 day
fewer collagen fibrils are translocated, because cells have fewer
attachments to collagen fibrils. PCLs with vascular SMCs
show the least lattice contraction. The possible reason appears related to reduced cell elongation and more cell-cell contacts, generating less cell-collagen contacts.
Another possible reason that vascular SMCs contract
PCLs less effectively is a difference in the mechanism for generating myosin ATPase activity. In attached cell PCLs the
developing cell tension results from sustained myosin ATPase
activity, requiring MLC-serine-19 to be retained in a chronic
phosphorylated state. Evidence supports the notion that the
regulation of MLC phosphatase in SMCs is primarily mediated via CPI-17 (see figure 5), whereas in non-muscle cell lines
like fibroblasts another pathway involving Rho-Rho kinase
phosphorylation of MLC phosphatase, involving the myosinbinding subunit is more important [8].
Y-27632 inhibits ROCK kinase, which phosphorylates a
specific tyrosine residue in one of the 4 peptide subunits of
MLC phosphatase and inactivates the enzyme [33]. In the absence of MLC phosphatase activity, MLC-serine-19 remains in
J. C. Dallon & H. Paul Ehrlich
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f
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h

Fig. 3: Fluorescent staining of cells in PCL is presented, where α-SMA is stained red, phalloidin-stained microfilaments stained green and the nuclei stained
blue. Panel a) is a myofibroblast in an attached PCL on day 4 just before release. Panel b) shows a contracted myofibroblasts 10 minutes after release of
an attached 4 day myofibroblast PCL. Panel c) shows two attached fibroblast PCL 1 day after casting and panel d) shows two fibroblasts within a 1 day old
fibroblast PCL 10 minutes after release. Panel 3e shows two cells in a 4 day old fibroblast PCL treated with vanadate for 24 hrs and panel 3f shows a fibroblast
10 minutes after release in a vanadate treated PCL. Panel 3g shows a vascular SMC in a PCL for 4 days and panel 3h shows vascular SMCs 10 min after release
of an attached SMC-PCL.

a phosphorylated state, generating sustained myosin ATPase
activity. Treating attached myofibroblast PCL with Y-27632
inhibits lattice contraction. It appears Y-27632 restores MLC
phosphatase activity resulting in the loss of sustained myosin
ATPase activity. In smooth muscle cells CPI-17, not found in
fibroblasts, is a more important regulator of the MLC phos-
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phatase activity. CPI-17 is phosphorylated by protein kinase
C and Rho kinase at Thr-38, which causes the inhibition of
MLC phosphatase [8]. Y-27632 inhibited contraction in the
SMC by 33% initially and by 57% at 5 hours. This is consistent with the finding that Y-27632 inhibits phosphorylation
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Table 2: Summary of results for ADR collagen lattice contraction

Released on Day 4
Myofibroblasts 10-15 minutes

Genistein
No effect
1.1 4E-4L
No effect
1.2 4E-4L
No effect
1.1 2E-4L
No effect
1.1 2E-4L

Myofibroblasts 5 hours
SMC 10-15 minutes
SMC 5 hours

Vanadate
Less contraction
1.5 4E-4L
Less contraction
1.6 4E-4L
No effect
1.1 2E-4L
No effect
0.94 2E-4L

ML-7
No effect
1.0 1E-4L
No effect
1.0 1E-4L
No effect
1.2 2E-4L
No effect
1.2 2E-4L

No Treatment Release Day 1
contracted 11%
contracted -0.03% NS

Fibroblasts
SMC

Y-27632
No effect
1.7 1E-3L
Much less contraction
4.2 1E-3L
Less contraction
1.2 2E-4L
No effect
1.2 2E-4L

No Treatment Release Day 4
contracted 52%
contracted 6%

No effect or NS indicates not statistically significant. The first number in the top part of the table is the ratio of the average treated lattice area over the
control. The 4E-4L indicates 4 experiments with 4 lattices in each experiment. The results given for 1 experiment are consistent with results when the
experiment was repeated two more times.
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Fig. 4: Part of the pathway for myosin regulation is shown for myofibroblasts (left) and smooth muscle cells (right). CPI-17 found in smooth muscle cells is
the regulator for the deactivation of MLC phosphatase, resulting in sustained myosin ATPase. In contrast, Rho kinase regulates MLC phosphatase activity
within myofibroblasts.

of CPI-17 at Thr-38 and reduces forces generated by
smooth muscle cells [8].
Vanadate limits tyrosine phosphatase activity and has a
more subtle effect at restoring MLC phosphatase activity in
fibroblast derived PCLs. It is ineffective at blocking sustained
myosin ATPase activity in vascular SMC compared to fibroblasts and myofibroblasts. Two possible explanations are that
vanadate does not affect the CPI-17 pathway, or it reinforces
the pathway. The Tyr42 domain in CPI-17 is necessary to
protect the dephosphorylation of MLC phosphatase regulatory peptide at Thr-38 [34, 35]. Phosphorylation of CPI-17
at Thr-38 activates its inhibitory affect on MLC phosphatase.
Vanadate may alter MLC phosphatase activity, utilizing the
same pathway.
Genistein and ML-7 do not affect ADR lattice contraction
populated with either myofibroblasts or SMCs. The MLCK
inhibitor ML-7 has no affect upon ADR cell PCL contraction,
because MLCK phosphorylation of MLC plays a minor role
in sustained myosin ATPase activity [33]. ROCK inactivation of MLC phosphatase maintains MLC in a phosphorylated
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state preserving cell tension. Genistein, a protein tyrosine kinase inhibitor, failed to alter ADR lattice contraction, which
suggests unphosphorylated tyrosine protein residues promotes
sustained myosin ATPase activity. In contrast to ADR lattice contraction by sustained myosin ATPase, genistein inhibits rapid myosin ATPase activity, which is responsible for
free floating fibroblast PCL contraction [29]. Vanadate has
no inhibitory action on smooth muscle cell PCL contraction,
but inhibits myofibroblast PCL contraction. Again it demonstrates differences in the sustained myosin ATPase activity between SMCs and myofibroblasts. Vanadate inhibits sustained
myosin ATPase activity and the development of cell tension.
In the absence of cell tension the transformation of fibroblasts into myofibroblasts is retarded. Vanadate treated SMC
PCL contraction may be unaffected, because their dependence
upon CPI-17 may preserve sustained myosin ATPase activity
In conclusion, although both human myofibroblasts and
rat SMCs can contract ADR collagen lattices by sustained
myosin ATPase activity, the pathway generating the sustained
myosin ATPase is different. That difference in generating
myosin ATPase is evident by the differences in response to
J. C. Dallon & H. Paul Ehrlich

vanadate and Y-27632. In addition, SMC are not effective at
contracting ADR lattices, perhaps due to what appears to be
less interaction between cells and collagen fibrils.
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